Stoke Therapeutics, Inc. Common Stock

STOKNASDAQ • USD
26.95 USD
↗ 0.27 (1.01%)🟢LIVE (AS OF 10:16 AM EST)
🟢Market: OPEN

Shares of Stoke Therapeutics, Inc. Common Stock (STOK) are trading at $26.95. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, STOK trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 13, 2026.

Open?$26.68
High?$27.14
Low?$26.46
Prev. Close?$26.68
Volume?47.3K
Avg. Volume?1.2M
VWAP?$26.93
Rel. Volume?0.04x
Bid / Ask
Bid?$26.53 × 100
Ask?$27.11 × 100
Spread?$0.58
Midpoint?$26.82
Valuation & Ratios
Market Cap?1.7B
Shares Out?65.4M
Float?54.4M
Float %?84.3%
P/E Ratio?N/A
P/B Ratio?4.95
EPS?-$3.72
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Employees
170
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2019-06-19
Address
45 WIGGINS AVENUE
BEDFORD, MA 01730
Phone: 781-430-8200
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
73
Short Sent.?
25
Piotroski F-Score?1/9Weak
Altman Z-Score?15.88Safe
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.71%High
Short Interest?10.7M
Days to Cover?6.8
Free Float54.4M
Avg Daily Volume1.6M
Settlement Date2026-10-30
Financial Health
Current Ratio?7.24Strong
Quick Ratio?7.24Strong
Cash Ratio?2.19Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
37
4.95FAIR▾
P/S?
Peers
100
S&P
3
61.86HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
58.05HIGH▾
Returns & Efficiency
ROE?
S&P
3
-69.0%WEAK▾
ROA?
S&P
3
-59.8%WEAK▾
Cash Flow & Enterprise
FCF?$-187656000
Enterprise Value?$1.6B
Fundamentals ratios updated end of day